IMUC
ImmunoCellular Therapeutics, Ltd.
IMUC
IMUC
Delisted
IMUC was delisted on the 16th of October, 2018.
39 hedge funds and large institutions have $3.56M invested in ImmunoCellular Therapeutics, Ltd. in 2014 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 8 increasing their positions, 11 reducing their positions, and 5 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
less funds holding
Funds holding: →
less capital invested
Capital invested by funds: $ → $
less repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
60% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 5
Holders
39
Holding in Top 10
–
Calls
$71K
Puts
$4K
Top Buyers
| 1 | +$196K | |
| 2 | +$44.9K | |
| 3 | +$41.1K | |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$35.2K |
| 5 |
D.E. Shaw & Co
New York
|
+$12.4K |
Top Sellers
| 1 | -$111K | |
| 2 | -$92.1K | |
| 3 | -$54.6K | |
| 4 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$42K |
| 5 |
GC
Guggenheim Capital
Chicago,
Illinois
|
-$25K |